Cancer therapy targeted at cellular signal transduction mechanisms: Strategies, clinical results, and unresolved issues

European Journal of Pharmacology

Volumn 625, Issue 1-3, 2009, Pages 6-22

  Christoffersen, Thoralf ^a   Guren, Tormod K ^b   Spindler, Karen Lise Garm ^c   Dahl, Olav ^d   Lønning, Per Eystein ^d   Gjertsen, Bjørn Tore ^d  

^a UNIVERSITY OF OSLO   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c LILLEBAELT HOSPITAL   (Denmark)

^d UNIVERSITY OF BERGEN   (Norway)

Author keywords

Antineoplastic drug; Cancer; Signal inhibitor; Signal transduction; Targeted therapy

Indexed keywords

AFINITOR; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; BORTEZOMIB; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DASATINIB; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; EVEROLIMUS; FLUOROPYRIMIDINE DERIVATIVE; GEFITINIB; GLUCOCORTICOID; IMATINIB; IRINOTECAN; LAPATINIB; LENALIDOMIDE; MELPHALAN; NILOTINIB; OXALIPLATIN; PANITUMUMAB; PERTUZUMAB; RO 4368451; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; TEMSIROLIMUS; THALIDOMIDE; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CELL; CANCER STEM CELL; CANCER THERAPY; CELL INTERACTION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG TARGETING; ENZYME INHIBITION; GASTROINTESTINAL STROMAL TUMOR; HEAD AND NECK CANCER; HUMAN; HYPERTENSION; KIDNEY CANCER; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MELANOMA; MOLECULAR MECHANICS; MULTIPLE MYELOMA; MUTATION; MYELOID LEUKEMIA; ONCOGENE; PANCREAS CANCER; PRIORITY JOURNAL; RASH; REVIEW; SIGNAL TRANSDUCTION; STROMA CELL; TUMOR VASCULARIZATION;

EID: 71749091181     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.10.009     Document Type: Review

References (226)

1. Adams J. The proteasome: a suitable antineoplastic target. Nat. Rev. Cancer 4 (2004) 349-360
2. Adams G.P., and Weiner L.M. Monoclonal antibody therapy of cancer. Nat. Biotechnol. 23 (2005) 1147-1157
3. Agero A.L., Dusza S.W., Benvenuto-Andrade C., Busam K.J., Myskowski P., and Halpern A.C. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J. Am. Acad. Dermatol. 55 (2006) 657-670
4. Aggarwal B.B., Sethi G., Baladandayuthapani V., Krishnan S., and Shishodia S. Targeting cell signaling pathways for drug discovery: an old lock needs a new key. J. Cell. Biochem. 102 (2007) 580-592
5. Amado R.G., Wolf M., Peeters M., Van Cutsem E., Siena S., Freeman D.J., Juan T., Sikorski R., Suggs S., Radinsky R., Patterson S.D., and Chang D.D. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26 (2008) 1626-1634
6. Appels N.M., Beijnen J.H., and Schellens J.H. Development of farnesyl transferase inhibitors: a review. Oncologist 10 (2005) 565-578
7. Argiris A., Karamouzis M.V., Raben D., and Ferris R.L. Head and neck cancer. Lancet 371 (2008) 1695-1709
8. Arslan M.A., Kutuk O., and Basaga H. Protein kinases as drug targets in cancer. Curr. Cancer Drug Targets 6 (2006) 623-634
9. Balkwill F. Cancer and the chemokine network. Nat. Rev. Cancer 4 (2004) 540-550
10. Bareschino M.A., Schettino C., Troiani T., Martinelli E., Morgillo F., and Ciardiello F. Erlotinib in cancer treatment. Ann. Oncol. 18 Suppl 6 (2007) vi35-41
11. Baselga J., Tripathy D., Mendelsohn J., Baughman S., Benz C.C., Dantis L., Sklarin N.T., Seidman A.D., Hudis C.A., Moore J., Rosen P.P., Twaddell T., Henderson I.C., and Norton L. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin. Oncol. 26 (1999) 78-83
12. Basseres D.S., and Baldwin A.S. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 25 (2006) 6817-6830
13. Bhowmick N.A., Neilson E.G., and Moses H.L. Stromal fibroblasts in cancer initiation and progression. Nature 432 (2004) 332-337
14. Bianchi G., Oliva L., Cascio P., Pengo N., Fontana F., Cerruti F., Orsi A., Pasqualetto E., Mezghrani A., Calbi V., Palladini G., Giuliani N., Anderson K.C., Sitia R., and Cenci S. The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood 113 (2009) 3040-3049
15. Bissell M.J., and Radisky D. Putting tumours in context. Nat. Rev. Cancer 1 (2001) 46-54
16. Blank U., Karlsson G., and Karlsson S. Signaling pathways governing stem-cell fate. Blood 111 (2008) 492-503
17. Blanke C.D., Rankin C., Demetri G.D., Ryan C.W., von Mehren M., Benjamin R.S., Raymond A.K., Bramwell V.H., Baker L.H., Maki R.G., Tanaka M., Hecht J.R., Heinrich M.C., Fletcher C.D., Crowley J.J., and Borden E.C. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J. Clin. Oncol. 26 (2008) 626-632
18. Blume-Jensen P., and Hunter T. Oncogenic kinase signalling. Nature 411 (2001) 355-365
19. Bokemeyer C., Bondarenko I., Makhson A., Hartmann J.T., Aparicio J., de Braud F., Donea S., Ludwig H., Schuch G., Stroh C., Loos A.H., Zubel A., and Koralewski P. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 27 (2009) 663-671
20. Bonner J.A., Harari P.M., Giralt J., Azarnia N., Shin D.M., Cohen R.B., Jones C.U., Sur R., Raben D., Jassem J., Ove R., Kies M.S., Baselga J., Youssoufian H., Amellal N., Rowinsky E.K., and Ang K.K. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 354 (2006) 567-578
21. Buchdunger E., Cioffi C.L., Law N., Stover D., Ohno-Jones S., Druker B.J., and Lydon N.B. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J. Pharmacol. Exp. Ther. 295 (2000) 139-145
22. Buday L., and Downward J. Many faces of Ras activation. Biochim. Biophys. Acta 1786 (2008) 178-187
23. Cantley L.C. The phosphoinositide 3-kinase pathway. Science 296 (2002) 1655-1657
24. Capdeville R., Buchdunger E., Zimmermann J., and Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat. Rev. Drug Discov. 1 (2002) 493-502
25. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 438 (2005) 932-936
26. Chau I., and Cunningham D. Treatment in advanced colorectal cancer: what, when and how?. Br. J. Cancer 100 (2009) 1704-1719
27. Cheng A.L., Kang Y.K., Chen Z., Tsao C.J., Qin S., Kim J.S., Luo R., Feng J., Ye S., Yang T.S., Xu J., Sun Y., Liang H., Liu J., Wang J., Tak W.Y., Pan H., Burock K., Zou J., Voliotis D., and Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10 (2009) 25-34
28. Chow L.Q., and Eckhardt S.G. Sunitinib: from rational design to clinical efficacy. J. Clin. Oncol. 25 (2007) 884-896
29. Christofori G. New signals from the invasive front. Nature 441 (2006) 444-450
30. Chung K.Y., Shia J., Kemeny N.E., Shah M., Schwartz G.K., Tse A., Hamilton A., Pan D., Schrag D., Schwartz L., Klimstra D.S., Fridman D., Kelsen D.P., and Saltz L.B. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J. Clin. Oncol. 23 (2005) 1803-1810
31. Ciardiello F., and Tortora G. EGFR antagonists in cancer treatment. N. Engl. J. Med. 358 (2008) 1160-1174
32. Comoglio P.M., Giordano S., and Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat. Rev. Drug Discov. 7 (2008) 504-516
33. Cross M.J., and Claesson-Welsh L. FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol. Sci. 22 (2001) 201-207
34. Cully M., You H., Levine A.J., and Mak T.W. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat. Rev. Cancer 6 (2006) 184-192
35. Daher I.N., and Yeh E.T. Vascular complications of selected cancer therapies. Nat. Clin. Pract. Cardiovasc. Med. 5 (2008) 797-805
36. D'Amato R.J., Loughnan M.S., Flynn E., and Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 4082-4085
37. Dancey J.E. Therapeutic targets: MTOR and related pathways. Cancer Biol. Ther. 5 (2006) 1065-1073
38. Dancey J.E., and Chen H.X. Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat. Rev. Drug Discov. 5 (2006) 649-659
39. de Jonge M.J., and Verweij J. Multiple targeted tyrosine kinase inhibition in the clinic: all for one or one for all?. Eur. J. Cancer 42 (2006) 1351-1356
40. Deininger M.W. Nilotinib. Clin. Cancer Res. 14 (2008) 4027-4031
41. Deininger M.W., and Druker B.J. Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol. Rev. 55 (2003) 401-423
42. Dematteo R.P., Ballman K.V., Antonescu C.R., Maki R.G., Pisters P.W., Demetri G.D., Blackstein M.E., Blanke C.D., von Mehren M., Brennan M.F., Patel S., McCarter M.D., Polikoff J.A., Tan B.R., and Owzar K. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 373 (2009) 1097-1104
43. Demetri G.D., von Mehren M., Blanke C.D., Van den Abbeele A.D., Eisenberg B., Roberts P.J., Heinrich M.C., Tuveson D.A., Singer S., Janicek M., Fletcher J.A., Silverman S.G., Silberman S.L., Capdeville R., Kiese B., Peng B., Dimitrijevic S., Druker B.J., Corless C., Fletcher C.D., and Joensuu H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347 (2002) 472-480
44. Demetri G.D., van Oosterom A.T., Garrett C.R., Blackstein M.E., Shah M.H., Verweij J., McArthur G., Judson I.R., Heinrich M.C., Morgan J.A., Desai J., Fletcher C.D., George S., Bello C.L., Huang X., Baum C.M., and Casali P.G. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368 (2006) 1329-1338
45. Dhillon S., and Wagstaff A.J. Lapatinib. Drugs 67 (2007) 2101-2108 discussion 2109-2110
46. Dhillon A.S., Hagan S., Rath O., and Kolch W. MAP kinase signalling pathways in cancer. Oncogene 26 (2007) 3279-3290
47. Di Cosimo S., and Baselga J. Targeted therapies in breast cancer: where are we now?. Eur. J. Cancer 44 (2008) 2781-2790
48. Dimopoulos M., Spencer A., Attal M., Prince H.M., Harousseau J.L., Dmoszynska A., San Miguel J., Hellmann A., Facon T., Foa R., Corso A., Masliak Z., Olesnyckyj M., Yu Z., Patin J., Zeldis J.B., and Knight R.D. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N. Engl. J. Med. 357 (2007) 2123-2132
49. Ding L., Getz G., Wheeler D.A., Mardis E.R., McLellan M.D., Cibulskis K., Sougnez C., Greulich H., Muzny D.M., Morgan M.B., Fulton L., Fulton R.S., Zhang Q., Wendl M.C., Lawrence M.S., Larson D.E., Chen K., Dooling D.J., Sabo A., Hawes A.C., Shen H., Jhangiani S.N., Lewis L.R., Hall O., Zhu Y., Mathew T., Ren Y., Yao J., Scherer S.E., Clerc K., Metcalf G.A., Ng B., Milosavljevic A., Gonzalez-Garay M.L., Osborne J.R., Meyer R., Shi X., Tang Y., Koboldt D.C., Lin L., Abbott R., Miner T.L., Pohl C., Fewell G., Haipek C., Schmidt H., Dunford-Shore B.H., Kraja A., Crosby S.D., Sawyer C.S., Vickery T., Sander S., Robinson J., Winckler W., Baldwin J., Chirieac L.R., Dutt A., Fennell T., Hanna M., Johnson B.E., Onofrio R.C., Thomas R.K., Tonon G., Weir B.A., Zhao X., Ziaugra L., Zody M.C., Giordano T., Orringer M.B., Roth J.A., Spitz M.R., Wistuba I.I., Ozenberger B., Good P.J., Chang A.C., Beer D.G., Watson M.A., Ladanyi M., Broderick S., Yoshizawa A., Travis W.D., Pao W., Province M.A., Weinstock G.M., Varmus H.E., Gabriel S.B., Lander E.S., Gibbs R.A., Meyerson M., and Wilson R.K. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455 (2008) 1069-1075
50. Dlugosz, A.A., Talpaz, M., 2009. Following the hedgehog to new cancer therapies. N. Engl. J. Med., published online September 2, at NEJM.org.
51. Druker B.J. Translation of the Philadelphia chromosome into therapy for CML. Blood 112 (2008) 4808-4817
52. Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal G.M., Fanning S., Zimmermann J., and Lydon N.B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2 (1996) 561-566
53. Druker B.J., Sawyers C.L., Kantarjian H., Resta D.J., Reese S.F., Ford J.M., Capdeville R., and Talpaz M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344 (2001) 1038-1042
54. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M., Lydon N.B., Kantarjian H., Capdeville R., Ohno-Jones S., and Sawyers C.L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344 (2001) 1031-1037
55. Druker B.J., Guilhot F., O'Brien S.G., Gathmann I., Kantarjian H., Gattermann N., Deininger M.W., Silver R.T., Goldman J.M., Stone R.M., Cervantes F., Hochhaus A., Powell B.L., Gabrilove J.L., Rousselot P., Reiffers J., Cornelissen J.J., Hughes T., Agis H., Fischer T., Verhoef G., Shepherd J., Saglio G., Gratwohl A., Nielsen J.L., Radich J.P., Simonsson B., Taylor K., Baccarani M., So C., Letvak L., and Larson R.A. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355 (2006) 2408-2417
56. Duronio V. The life of a cell: apoptosis regulation by the PI3K/PKB pathway. Biochem. J. 415 (2008) 333-344
57. Dy G.K., and Adjei A.A. Systemic cancer therapy: evolution over the last 60 years. Cancer 113 (2008) 1857-1887
58. Ebos J.M., Lee C.R., Cruzz-Monos W., Bjarnason G.A., Christensen J.G., and Kerbel R.S. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15 (2009) 232-239
59. Eisen T., Ahmad T., Flaherty K.T., Gore M., Kaye S., Marais R., Gibbens I., Hackett S., James M., Schuchter L.M., Nathanson K.L., Xia C., Simantov R., Schwartz B., Poulin-Costello M., O'Dwyer P.J., and Ratain M.J. Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis. Br. J. Cancer 95 (2006) 581-586
60. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., Lindeman N., Gale C.M., Zhao X., Christensen J., Kosaka T., Holmes A.J., Rogers A.M., Cappuzzo F., Mok T., Lee C., Johnson B.E., Cantley L.C., and Janne P.A. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316 (2007) 1039-1043
61. Eskens F.A., and Sleijfer S. The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: where does it fit?. Eur. J. Cancer 44 (2008) 2350-2356
62. Eyler C.E., and Rich J.N. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J. Clin. Oncol. 26 (2008) 2839-2845
63. Fabbro D., Ruetz S., Buchdunger E., Cowan-Jacob S.W., Fendrich G., Liebetanz J., Mestan J., O'Reilly T., Traxler P., Chaudhuri B., Fretz H., Zimmermann J., Meyer T., Caravatti G., Furet P., and Manley P.W. Protein kinases as targets for anticancer agents: from inhibitors to useful drugs. Pharmacol. Ther. 93 (2002) 79-98
64. Faderl S., Talpaz M., Estrov Z., O'Brien S., Kurzrock R., and Kantarjian H.M. The biology of chronic myeloid leukemia. N. Engl. J. Med. 341 (1999) 164-172
65. Faivre S., Kroemer G., and Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat. Rev. Drug Discov 5 (2006) 671-688
66. Faivre S., Demetri G., Sargent W., and Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat. Rev. Drug Discov 6 (2007) 734-745
67. Felsher D.W. Tumor dormancy and oncogene addiction. APMIS 116 (2008) 629-637
68. Ferrara N., Hillan K.J., Gerber H.P., and Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov 3 (2004) 391-400
69. Flaherty K., Puzanov I., Sosman J., Kim K., Ribas A., McArthur G., Lee R.J., Grippo J.F., Nolop K., and Chapman P. Phase I study of PLX4032: proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J. Clin. Oncol. 27 suppl (2009) 15s abstract #9000, ASCO 2009
70. Fletcher J.A., and Rubin B.P. KIT mutations in GIST. Curr. Opin. Genet. Dev. 17 (2007) 3-7
71. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285 (1971) 1182-1186
72. Folkman J. Angiogenesis: an organizing principle for drug discovery?. Nat. Rev. Drug Discov 6 (2007) 273-286
73. Franks M.E., Macpherson G.R., and Figg W.D. Thalidomide. Lancet 363 (2004) 1802-1811
74. Fukumura D., and Jain R.K. Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc. Res. 74 (2007) 72-84
75. Gajiwala K.S., Wu J.C., Christensen J., Deshmukh G.D., Diehl W., DiNitto J.P., English J.M., Greig M.J., He Y.A., Jacques S.L., Lunney E.A., McTigue M., Molina D., Quenzer T., Wells P.A., Yu X., Zhang Y., Zou A., Emmett M.R., Marshall A.G., Zhang H.M., and Demetri G.D. KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc. Natl. Acad. Sci. U. S. A. 106 (2009) 1542-1547
76. Gambacorti-Passerini C.B., Gunby R.H., Piazza R., Galietta A., Rostagno R., and Scapozza L. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol. 4 (2003) 75-85
77. Geyer C.E., Forster J., Lindquist D., Chan S., Romieu C.G., Pienkowski T., Jagiello-Gruszfeld A., Crown J., Chan A., Kaufman B., Skarlos D., Campone M., Davidson N., Berger M., Oliva C., Rubin S.D., Stein S., and Cameron D. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 355 (2006) 2733-2743
78. Ghaneh P., Costello E., and Neoptolemos J.P. Biology and management of pancreatic cancer. Gut 56 (2007) 1134-1152
79. Ghoreschi K., Laurence A., and O'Shea J.J. Selectivity and therapeutic inhibition of kinases: to be or not to be?. Nat. Immunol. 10 (2009) 356-360
80. Giantonio B.J., Catalano P.J., Meropol N.J., O'Dwyer P.J., Mitchell E.P., Alberts S.R., Schwartz M.A., and Benson III A.B. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol. 25 (2007) 1539-1544
81. Gold K.A., Lee H.Y., and Kim E.S. Targeted therapies in squamous cell carcinoma of the head and neck. Cancer 115 (2009) 922-935
82. Gomez H.L., Doval D.C., Chavez M.A., Ang P.C., Aziz Z., Nag S., Ng C., Franco S.X., Chow L.W., Arbushites M.C., Casey M.A., Berger M.S., Stein S.H., and Sledge G.W. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J. Clin. Oncol. 26 (2008) 2999-3005
83. Grant S.K. Therapeutic protein kinase inhibitors. Cell. Mol. Life Sci. 66 (2009) 1163-1177
84. Greten T.F., Korangy F., Manns M.P., and Malek N.P. Molecular therapy for the treatment of hepatocellular carcinoma. Br. J. Cancer 100 (2009) 19-23
85. Gruber F., Mustjoki S., and Porkka K. Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome-positive acute lymphoblastic leukaemia. Br. J. Haematol. 145 (2009) 581-597
86. Gschwind A., Fischer O.M., and Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat. Rev. Cancer 4 (2004) 361-370
87. Guertin D.A., and Sabatini D.M. Defining the role of mTOR in cancer. Cancer Cell 12 (2007) 9-22
88. Hait W.N., and Hambley T.W. Targeted cancer therapeutics. Cancer Res. 69 (2009) 1263-1267 discussion 1267
89. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
90. Harris A.L. Hypoxia-a key regulatory factor in tumour growth. Nat. Rev. Cancer 2 (2002) 38-47
91. Harris R.C., Chung E., and Coffey R.J. EGF receptor ligands. Exp. Cell Res. 284 (2003) 2-13
92. Haubruck H., and McCormick F. Ras p21: effects and regulation. Biochim. Biophys. Acta 1072 (1991) 215-229
93. Hecht J.R., Mitchell E., Chidiac T., Scroggin C., Hagenstad C., Spigel D., Marshall J., Cohn A., McCollum D., Stella P., Deeter R., Shahin S., and Amado R.G. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J. Clin. Oncol. 27 (2009) 672-680
94. Heinrich M.C., Corless C.L., Duensing A., McGreevey L., Chen C.J., Joseph N., Singer S., Griffith D.J., Haley A., Town A., Demetri G.D., Fletcher C.D., and Fletcher J.A. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299 (2003) 708-710
95. Heldin C.H., Rubin K., Pietras K., and Ostman A. High interstitial fluid pressure - an obstacle in cancer therapy. Nat. Rev. Cancer 4 (2004) 806-813
96. Hicklin D.J., and Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. 23 (2005) 1011-1027
97. Hida T., Ogawa S., Park J.C., Park J.Y., Shimizu J., Horio Y., and Yoshida K. Gefitinib for the treatment of non-small-cell lung cancer. Expert Rev. Anticancer Ther. 9 (2009) 17-35
98. Hill R., and Wu H. PTEN, stem cells, and cancer stem cells. J. Biol. Chem. 284 (2009) 11755-11759
99. Hochhaus A., Baccarani M., Deininger M., Apperley J.F., Lipton J.H., Goldberg S.L., Corm S., Shah N.P., Cervantes F., Silver R.T., Niederwieser D., Stone R.M., Dombret H., Larson R.A., Roy L., Hughes T., Muller M.C., Ezzeddine R., Countouriotis A.M., and Kantarjian H.M. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 22 (2008) 1200-1206
100. Hochhaus A., O'Brien S.G., Guilhot F., Druker B.J., Branford S., Foroni L., Goldman J.M., Muller M.C., Radich J.P., Rudoltz M., Mone M., Gathmann I., Hughes T.P., and Larson R.A. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 23 (2009) 1054-1061
101. Hudis C.A. Trastuzumab-mechanism of action and use in clinical practice. N. Engl. J. Med. 357 (2007) 39-51
102. Hunter T. Tyrosine phosphorylation: thirty years and counting. Curr. Opin. Cell Biol. 21 (2009) 140-146
103. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J., Baron A., Griffing S., Holmgren E., Ferrara N., Fyfe G., Rogers B., Ross R., and Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350 (2004) 2335-2342
104. Hynes N.E., and Lane H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 5 (2005) 341-354
105. Hynes N.E., and MacDonald G. ErbB receptors and signaling pathways in cancer. Curr. Opin. Cell Biol. 21 (2009) 177-184
106. Iiizumi M., Liu W., Pai S.K., Furuta E., and Watabe K. Drug development against metastasis-related genes and their pathways: a rationale for cancer therapy. Biochim. Biophys. Acta 1786 (2008) 87-104
107. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307 (2005) 58-62
108. Joensuu H., Roberts P.J., Sarlomo-Rikala M., Andersson L.C., Tervahartiala P., Tuveson D., Silberman S., Capdeville R., Dimitrijevic S., Druker B., and Demetri G.D. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N. Engl. J. Med. 344 (2001) 1052-1056
109. Jones S., Zhang X., Parsons D.W., Lin J.C., Leary R.J., Angenendt P., Mankoo P., Carter H., Kamiyama H., Jimeno A., Hong S.M., Fu B., Lin M.T., Calhoun E.S., Kamiyama M., Walter K., Nikolskaya T., Nikolsky Y., Hartigan J., Smith D.R., Hidalgo M., Leach S.D., Klein A.P., Jaffee E.M., Goggins M., Maitra A., Iacobuzio-Donahue C., Eshleman J.R., Kern S.E., Hruban R.H., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., Velculescu V.E., and Kinzler K.W. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321 (2008) 1801-1806
110. Jonker D.J., O'Callaghan C.J., Karapetis C.S., Zalcberg J.R., Tu D., Au H.J., Berry S.R., Krahn M., Price T., Simes R.J., Tebbutt N.C., van Hazel G., Wierzbicki R., Langer C., and Moore M.J. Cetuximab for the treatment of colorectal cancer. N. Engl. J. Med. 357 (2007) 2040-2048
111. Jordan C.T., Guzman M.L., and Noble M. Cancer stem cells. N. Engl. J. Med. 355 (2006) 1253-1261
112. Jorissen R.N., Walker F., Pouliot N., Garrett T.P., Ward C.W., and Burgess A.W. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp. Cell Res. 284 (2003) 31-53
113. Joyce J.A., and Pollard J.W. Microenvironmental regulation of metastasis. Nat. Rev. Cancer 9 (2009) 239-252
114. Junttila T.T., Akita R.W., Parsons K., Fields C., Lewis Phillips G.D., Friedman L.S., Sampath D., and Sliwkowski M.X. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 15 (2009) 429-440
115. Kaelin Jr. W.G. The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin. Cancer Res. 13 (2007) 680s-684s
116. Kalyankrishna S., and Grandis J.R. Epidermal growth factor receptor biology in head and neck cancer. J. Clin. Oncol. 24 (2006) 2666-2672
117. Karapetis C.S., Khambata-Ford S., Jonker D.J., O'Callaghan C.J., Tu D., Tebbutt N.C., Simes R.J., Chalchal H., Shapiro J.D., Robitaille S., Price T.J., Shepherd L., Au H.J., Langer C., Moore M.J., and Zalcberg J.R. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359 (2008) 1757-1765
118. Karnoub A.E., and Weinberg R.A. Ras oncogenes: split personalities. Nat. Rev. Mol. Cell Biol 9 (2008) 517-531
119. Kawamoto T., Sato J.D., Le A., Polikoff J., Sato G.H., and Mendelsohn J. Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc. Natl. Acad. Sci. U. S. A. 80 (1983) 1337-1341
120. Keifer J.A., Guttridge D.C., Ashburner B.P., and Baldwin Jr. A.S. Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J. Biol. Chem. 276 (2001) 22382-22387
121. Keniry M., and Parsons R. The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene 27 (2008) 5477-5485
122. Kerbel R.S. Tumor angiogenesis. N. Engl. J. Med. 358 (2008) 2039-2049
123. Kerbel R., and Folkman J. Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer 2 (2002) 727-739
124. Klonisch T., Wiechec E., Hombach-Klonisch S., Ande S.R., Wesselborg S., Schulze-Osthoff K., and Los M. Cancer stem cell markers in common cancers - therapeutic implications. Trends Mol. Med. 14 (2008) 450-460
125. Kumar S., and Rajkumar S.V. Thalidomide and lenalidomide in the treatment of multiple myeloma. Eur. J. Cancer 42 (2006) 1612-1622
126. Kumar S.K., Rajkumar S.V., Dispenzieri A., Lacy M.Q., Hayman S.R., Buadi F.K., Zeldenrust S.R., Dingli D., Russell S.J., Lust J.A., Greipp P.R., Kyle R.A., and Gertz M.A. Improved survival in multiple myeloma and the impact of novel therapies. Blood 111 (2008) 2516-2520
127. Kyle R.A., and Rajkumar S.V. Multiple myeloma. Blood 111 (2008) 2962-2972
128. Ladanyi M., and Pao W. Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. Mod. Path. 21 Suppl 2 (2008) S16-22
129. Lane H.A., and Breuleux M. Optimal targeting of the mTORC1 kinase in human cancer. Curr. Opin. Cell Biol. 21 (2009) 219-229
130. Laurent-Puig P., Lievre A., and Blons H. Mutations and response to epidermal growth factor receptor inhibitors. Clin. Cancer Res. 15 (2009) 1133-1139
131. Lewis T.S., Shapiro P.S., and Ahn N.G. Signal transduction through MAP kinase cascades. Adv. Cancer Res. 74 (1998) 49-139
132. Li F., Tiede B., Massague J., and Kang Y. Beyond tumorigenesis: cancer stem cells in metastasis. Cell Res. 17 (2007) 3-14
133. Linardou H., Dahabreh I.J., Kanaloupiti D., Siannis F., Bafaloukos D., Kosmidis P., Papadimitriou C.A., and Murray S. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol. 9 (2008) 962-972
134. Liotta L.A., and Kohn E.C. The microenvironment of the tumour-host interface. Nature 411 (2001) 375-379
135. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., de Oliveira A.C., Santoro A., Raoul J.L., Forner A., Schwartz M., Porta C., Zeuzem S., Bolondi L., Greten T.F., Galle P.R., Seitz J.F., Borbath I., Haussinger D., Giannaris T., Shan M., Moscovici M., Voliotis D., and Bruix J. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359 (2008) 378-390
136. Loges S., Mazzone M., Hohensinner P., and Carmeliet P. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell 15 (2009) 167-170
137. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.G., Louis D.N., Christiani D.C., Settleman J., and Haber D.A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350 (2004) 2129-2139
138. Ma W.W., and Adjei A.A. Novel agents on the horizon for cancer therapy. CA Cancer J. Clin. 59 (2009) 111-137
139. Maheswaran S., Sequist L.V., Nagrath S., Ulkus L., Brannigan B., Collura C.V., Inserra E., Diederichs S., Iafrate A.J., Bell D.W., Digumarthy S., Muzikansky A., Irimia D., Settleman J., Tompkins R.G., Lynch T.J., Toner M., and Haber D.J. Detection of mutations in EGFR in circulating lung-cancer cells. N. Engl. J. Med. 359 (2008) 366-377
140. Manning G., Whyte D.B., Martinez R., Hunter T., and Sudarsanam S. The protein kinase complement of the human genome. Science 298 (2002) 1912-1934
141. Mano M., and Humblet Y. Drug Insight: panitumumab, a human EGFR-targeted monoclonal antibody with promising clinical activity in colorectal cancer. Nat. Clin. Pract. Oncol. 5 (2008) 415-425
142. McCormick F. Small-molecule inhibitors of cell signaling. Curr. Opin. Biotechnol. 11 (2000) 593-597
143. Meloche S., and Pouyssegur J. The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene 26 (2007) 3227-3239
144. Michaloglou C., Vredeveld L.C., Mooi W.J., and Peeper D.S. BRAF(E600) in benign and malignant human tumours. Oncogene 27 (2008) 877-895
145. Miller V.A., Kris M.G., Shah N., Patel J., Azzoli C., Gomez J., Krug L.M., Pao W., Rizvi N., Pizzo B., Tyson L., Venkatraman E., Ben-Porat L., Memoli N., Zakowski M., Rusch V., and Heelan R.T. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J. Clin. Oncol. 22 (2004) 1103-1109
146. Mok T.S., Wu Y., Thongprasert S., Yang C., Chu D., Saijo N., Sunpweravong P., Han B., Margono B., Ichinose Y., Nishiwaki Y., Ohe Y., Yang J., Chewaskulyong B., Jiang H., Duffield E.L., Watkins C.L., Armour A.A., and Fukuoka M. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361 (2009) 947-957
147. Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Rixe O., Oudard S., Negrier S., Szczylik C., Kim S.T., Chen I., Bycott P.W., Baum C.M., and Figlin R.A. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356 (2007) 115-124
148. Mukherji D., and Spicer J. Second-generation epidermal growth factor tyrosine kinase inhibitors in non-small cell lung cancer. Expert Opin. Investig. Drugs 18 (2009) 293-301
149. Murdoch D., and Sager J. Will targeted therapy hold its promise? An evidence-based review. Curr. Opin. Oncol. 20 (2008) 104-111
150. Normanno N., De Luca A., Bianco C., Strizzi L., Mancino M., Maiello M.R., Carotenuto A., De Feo G., Caponigro F., and Salomon D.S. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366 (2006) 2-16
151. Nygren P., and Larsson R. Overview of the clinical efficacy of investigational anticancer drugs. J. Intern. Med. 253 (2003) 46-75
152. Ocio E.M., Mateos M.V., Maiso P., Pandiella A., and San-Miguel J.F. New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings. Lancet Oncol. 9 (2008) 1157-1165
153. Orlowski R.Z., and Kuhn D.J. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin. Cancer Res. 14 (2008) 1649-1657
154. Ottmann O.G., Druker B.J., Sawyers C.L., Goldman J.M., Reiffers J., Silver R.T., Tura S., Fischer T., Deininger M.W., Schiffer C.A., Baccarani M., Gratwohl A., Hochhaus A., Hoelzer D., Fernandes-Reese S., Gathmann I., Capdeville R., and O'Brien S.G. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 100 (2002) 1965-1971
155. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F.J., Lindeman N., Boggon T.J., Naoki K., Sasaki H., Fujii Y., Eck M.J., Sellers W.R., Johnson B.E., and Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
156. Paez-Ribes M., Allen E., Hudock J., Takeda T., Okuyama H., Vinals F., Inoue M., Bergers G., Hanahan D., and Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15 (2009) 220-231
157. Palumbo A., Facon T., Sonneveld P., Blade J., Offidani M., Gay F., Moreau P., Waage A., Spencer A., Ludwig H., Boccadoro M., and Harousseau J.L. Thalidomide for treatment of multiple myeloma: 10 years later. Blood 111 (2008) 3968-3977
158. Pao W., and Miller V.A. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J. Clin. Oncol. 23 (2005) 2556-2568
159. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., Singh B., Heelan R., Rusch V., Fulton L., Mardis E., Kupfer D., Wilson R., Kris M., and Varmus H. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 13306-13311
160. Paravar T., and Lee D.J. Thalidomide: mechanisms of action. Int. Rev. Immunol. 27 (2008) 111-135
161. Pedersen K., Angelini P.D., Laos S., Bach-Faig A., Cunningham M.P., Ferrer-Ramon C., Luque-Garcia A., Garcia-Castillo J., Parra-Palau J.L., Scaltriti M., Ramon y Cajal S., Arribas J., and Baselga J. A naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasis. Mol. Cell. Biol. 29 (2009) 3319-3331
162. Piccaluga P.P., Paolini S., and Martinelli G. Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Cancer 110 (2007) 1178-1186
163. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., Gianni L., Baselga J., Bell R., Jackisch C., Cameron D., Dowsett M., Barrios C.H., Steger G., Huang C.S., Andersson M., Inbar M., Lichinitser M., Lang I., Nitz U., Iwata H., Thomssen C., Lohrisch C., Suter T.M., Ruschoff J., Suto T., Greatorex V., Ward C., Straehle C., McFadden E., Dolci M.S., and Gelber R.D. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353 (2005) 1659-1672
164. Pirker R., Pereira J.R., Szczesna A., von Pawel J., Krzakowski M., Ramlau R., Vynnychenko I., Park K., Yu C.T., Ganul V., Roh J.K., Bajetta E., O'Byrne K., de Marinis F., Eberhardt W., Goddemeier T., Emig M., and Gatzemeier U. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 373 (2009) 1525-1531
165. Pollard J.W. Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer 4 (2004) 71-78
166. Ponder B.A. Cancer genetics. Nature 411 (2001) 336-341
167. Raab M.S., Podar K., Breitkreutz I., Richardson P.G., and Anderson K.C. Multiple myeloma. Lancet 374 (2009) 324-339
168. Rajalingam K., Schreck R., Rapp U.R., and Albert S. Ras oncogenes and their downstream targets. Biochim. Biophys. Acta 1773 (2007) 1177-1195
169. Ramirez P., and DiPersio J.F. Therapy options in imatinib failures. Oncologist 13 (2008) 424-434
170. Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat. Rev. Cancer 5 (2005) 172-183
171. Reya T., Morrison S.J., Clarke M.F., and Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 414 (2001) 105-111
172. Rini B.I., Campbell S.C., and Escudier B. Renal cell carcinoma. Lancet 373 (2009) 1119-1132
173. Rivera F., Lopez-Tarruella S., Vega-Villegas M.E., and Salcedo M. Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy. Cancer Treat. Rev. 35 (2009) 335-339
174. Roberts P.J., and Der C.J. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26 (2007) 3291-3310
175. Romond E.H., Perez E.A., Bryant J., Suman V.J., Geyer Jr. C.E., Davidson N.E., Tan-Chiu E., Martino S., Paik S., Kaufman P.A., Swain S.M., Pisansky T.M., Fehrenbacher L., Kutteh L.A., Vogel V.G., Visscher D.W., Yothers G., Jenkins R.B., Brown A.M., Dakhil S.R., Mamounas E.P., Lingle W.L., Klein P.M., Ingle J.N., and Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353 (2005) 1673-1684
176. Rosell R., Moran T., Queralt C., Porta R., Cardenal F., Camps C., Majem M., Lopwz-Vivanco G., Isla D., Provencio M., Insa A., Massuti B., Gonzales-Lariba J.L., Paz-Ares L., Bover I., Garcia-Campelo R., Moreno M.A., Catot S., Rolfo C., Reguart N., Palmero R., Sanches J.M., Bastus R., Mayo C., Bertran-Alamillo J., Molina M.A., Sanchez J.J., and Taron T. Screening for epidermal growth factor receptor mutations in lung cancer. N. Engl. J. Med. 361 (2009) 958-967
177. Rowinsky E.K. The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors. Annu. Rev. Med. 55 (2004) 433-457
178. Rubin B.P., Singer S., Tsao C., Duensing A., Lux M.L., Ruiz R., Hibbard M.K., Chen C.J., Xiao S., Tuveson D.A., Demetri G.D., Fletcher C.D., and Fletcher J.A. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res. 61 (2001) 8118-8121
179. Rubin B.P., Heinrich M.C., and Corless C.L. Gastrointestinal stromal tumour. Lancet 369 (2007) 1731-1741
180. Sabatini D.M. mTOR and cancer: insights into a complex relationship. Nat. Rev. Cancer 6 (2006) 729-734
181. San Miguel J.F., Schlag R., Khuageva N.K., Dimopoulos M.A., Shpilberg O., Kropff M., Spicka I., Petrucci M.T., Palumbo A., Samoilova O.S., Dmoszynska A., Abdulkadyrov K.M., Schots R., Jiang B., Mateos M.V., Anderson K.C., Esseltine D.L., Liu K., Cakana A., van de Velde H., and Richardson P.G. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N. Engl. J. Med. 359 (2008) 906-917
182. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., Lilenbaum R., and Johnson D.H. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355 (2006) 2542-2550
183. Sausville E.A., Elsayed Y., Monga M., and Kim G. Signal transduction-directed cancer treatments. Annu. Rev. Pharmacol. Toxicol. 43 (2003) 199-231
184. Sauter G., Lee J., Bartlett J.M., Slamon D.J., and Press M.F. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J. Clin. Oncol. 27 (2009) 1323-1333
185. Scaltriti M., Rojo F., Ocana A., Anido J., Guzman M., Cortes J., Di Cosimo S., Matias-Guiu X., Ramon y Cajal S., Arribas J., and Baselga J. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J. Natl. Cancer Inst. 99 (2007) 628-638
186. Schindler T., Bornmann W., Pellicena P., Miller W.T., Clarkson B., and Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289 (2000) 1938-1942
187. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 103 (2000) 211-225
188. Schmitz K.R., and Ferguson K.M. Interaction of antibodies with ErbB receptor extracellular regions. Exp. Cell Res. 315 (2009) 659-670
189. Schreck R., and Rapp U.R. Raf kinases: oncogenesis and drug discovery. Int. J. Cancer 119 (2006) 2261-2271
190. Schubbert S., Shannon K., and Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat. Rev. Cancer 7 (2007) 295-308
191. Sebolt-Leopold J.S., and English J.M. Mechanisms of drug inhibition of signalling molecules. Nature 441 (2006) 457-462
192. Sequist L.V., Martins R.G., Spigel D., Grunberg S.M., Spira A., Janne P.A., Joshi V.A., McCollum D., Evans T.L., Muzikansky A., Kuhlmann G.L., Han M., Goldberg J.S., Settleman J., Iafrate A.J., Engelman J.A., Haber D.A., Johnson B.E., and Lynch T.J. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J. Clin. Oncol. 26 (2008) 2442-2449
193. Sharma S.V., and Settleman J. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev. 21 (2007) 3214-3231
194. Sharma S.V., Bell D.W., Settleman J., and Haber D.A. Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer 7 (2007) 169-181
195. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., Campos D., Maoleekoonpiroj S., Smylie M., Martins R., van Kooten M., Dediu M., Findlay B., Tu D., Johnston D., Bezjak A., Clark G., Santabarbara P., and Seymour L. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353 (2005) 123-132
196. Singhal S., Mehta J., Desikan R., Ayers D., Roberson P., Eddlemon P., Munshi N., Anaissie E., Wilson C., Dhodapkar M., Zeddis J., and Barlogie B. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. 341 (1999) 1565-1571
197. Sjoblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K., Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., and Velculescu V.E. The consensus coding sequences of human breast and colorectal cancers. Science 314 (2006) 268-274
198. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., and McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987) 177-182
199. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., Baselga J., and Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344 (2001) 783-792
200. Socinski M.A. Antibodies to the epidermal growth factor receptor in non small cell lung cancer: current status of matuzumab and panitumumab. Clin. Cancer Res. 13 (2007) s4597-4601
201. Sordella R., Bell D.W., Haber D.A., and Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305 (2004) 1163-1167
202. Sorlie T., Tibshirani R., Parker J., Hastie T., Marron J.S., Nobel A., Deng S., Johnsen H., Pesich R., Geisler S., Demeter J., Perou C.M., Lonning P.E., Brown P.O., Borresen-Dale A.L., and Botstein D. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 8418-8423
203. Stewart D.J., and Kurzrock R. Cancer: the road to Amiens. J. Clin. Oncol. 27 (2009) 328-333
204. Stratton M.R., Campbell P.J., and Futreal P.A. The cancer genome. Nature 458 (2009) 719-724
205. Tabruyn S.P., and Griffioen A.W. Molecular pathways of angiogenesis inhibition. Biochem. Biophys. Res. Commun. 355 (2007) 1-5
206. Thatcher N., Chang A., Parikh P., Rodrigues Pereira J., Ciuleanu T., von Pawel J., Thongprasert S., Tan E.H., Pemberton K., Archer V., and Carroll K. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366 (2005) 1527-1537
207. Therapontos C., Erskine L., Gardner E.R., Figg W.D., and Vargesson N. Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation. Proc. Natl. Acad. Sci. U. S. A. 106 (2009) 8573-8578
208. Tol J., Koopman M., Cats A., Rodenburg C.J., Creemers G.J., Schrama J.G., Erdkamp F.L., Vos A.H., van Groeningen C.J., Sinnige H.A., Richel D.J., Voest E.E., Dijkstra J.R., Vink-Borger M.E., Antonini N.F., Mol L., van Krieken J.H., Dalesio O., and Punt C.J. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N. Engl. J. Med. 360 (2009) 563-572
209. Tsao M.S., Sakurada A., Cutz J.C., Zhu C.Q., Kamel-Reid S., Squire J., Lorimer I., Zhang T., Liu N., Daneshmand M., Marrano P., da Cunha Santos G., Lagarde A., Richardson F., Seymour L., Whitehead M., Ding K., Pater J., and Shepherd F.A. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N. Engl. J. Med. 353 (2005) 133-144
210. Vallet S., Palumbo A., Raje N., Boccadoro M., and Anderson K.C. Thalidomide and lenalidomide: mechanism-based potential drug combinations. Leuk. Lymphoma 49 (2008) 1238-1245
211. Van Cutsem E., Kohne C.H., Hitre E., Zaluski J., Chang Chien C.R., Makhson A., D'Haens G., Pinter T., Lim R., Bodoky G., Roh J.K., Folprecht G., Ruff P., Stroh C., Tejpar S., Schlichting M., Nippgen J., and Rougier P. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360 (2009) 1408-1417
212. Vermorken J.B., Mesia R., Rivera F., Remenar E., Kawecki A., Rottey S., Erfan J., Zabolotnyy D., Kienzer H.R., Cupissol D., Peyrade F., Benasso M., Vynnychenko I., De Raucourt D., Bokemeyer C., Schueler A., Amellal N., and Hitt R. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N. Engl. J. Med. 359 (2008) 1116-1127
213. Vincenzi B., Schiavon G., Silletta M., Santini D., and Tonini G. The biological properties of cetuximab. Crit. Rev. Oncol./Hematol. 68 (2008) 93-106
214. Vivanco I., and Sawyers C.L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer 2 (2002) 489-501
215. Vogelstein B., and Kinzler K.W. Cancer genes and the pathways they control. Nat. Med. 10 (2004) 789-799
216. Wang S.C., Lien H.C., Xia W., Chen I.F., Lo H.W., Wang Z., Ali-Seyed M., Lee D.F., Bartholomeusz G., Ou-Yang F., Giri D.K., and Hung M.C. Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. Cancer Cell 6 (2004) 251-261
217. Weber D.M., Chen C., Niesvizky R., Wang M., Belch A., Stadtmauer E.A., Siegel D., Borrello I., Rajkumar S.V., Chanan-Khan A.A., Lonial S., Yu Z., Patin J., Olesnyckyj M., Zeldis J.B., and Knight R.D. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N. Engl. J. Med. 357 (2007) 2133-2142
218. Weinstein I.B., and Joe A.K. Mechanisms of disease: oncogene addiction-a rationale for molecular targeting in cancer therapy. Nat. Clin. Pract. Oncol. 3 (2006) 448-457
219. Weisberg E., Manley P.W., Cowan-Jacob S.W., Hochhaus A., and Griffin J.D. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat. Rev. Cancer 7 (2007) 345-356
220. Wicha M.S., Liu S., and Dontu G. Cancer stem cells: an old idea-a paradigm shift. Cancer Res. 66 (2006) 1883-1890 discussion 1895-1886
221. Wilhelm S., Carter C., Lynch M., Lowinger T., Dumas J., Smith R.A., Schwartz B., Simantov R., and Kelley S. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat. Rev. Drug Discov. 5 (2006) 835-844
222. Wilhelm S.M., Adnane L., Newell P., Villanueva A., Llovet J.M., and Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol. Cancer Ther. 7 (2008) 3129-3140
223. Wong R., and Cunningham D. Using predictive biomarkers to select patients with advanced colorectal cancer for treatment with epidermal growth factor receptor antibodies. J. Clin. Oncol. 26 (2008) 5668-5670
224. Wood L.D., Parsons D.W., Jones S., Lin J., Sjoblom T., Leary R.J., Shen D., Boca S.M., Barber T., Ptak J., Silliman N., Szabo S., Dezso Z., Ustyanksky V., Nikolskaya T., Nikolsky Y., Karchin R., Wilson P.A., Kaminker J.S., Zhang Z., Croshaw R., Willis J., Dawson D., Shipitsin M., Willson J.K., Sukumar S., Polyak K., Park B.H., Pethiyagoda C.L., Pant P.V., Ballinger D.G., Sparks A.B., Hartigan J., Smith D.R., Suh E., Papadopoulos N., Buckhaults P., Markowitz S.D., Parmigiani G., Kinzler K.W., Velculescu V.E., and Vogelstein B. The genomic landscapes of human breast and colorectal cancers. Science 318 (2007) 1108-1113
225. Xia W., Gerard C.M., Liu L., Baudson N.M., Ory T.L., and Spector N.L. Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene 24 (2005) 6213-6221
226. Zandi R., Larsen A.B., Andersen P., Stockhausen M.T., and Poulsen H.S. Mechanisms for oncogenic activation of the epidermal growth factor receptor. Cell. Signal. 19 (2007) 2013-2023